On Thursday, Tissue Regenix (LON: TRX) warned shareholders that full year revenues would be 15-20% lower than projected after delays in developing manufacturing capabilities.

Tissue Regenix are a major medical device company, specializing in regenerative medicine. They have patented technology which removes DNA and other cellular material, allowing repair to diseased or worn out body parts.

In June, the Leeds based health firm said that annual revenue would be heavily weighted on the second half of the year.

Shareholders were warned that revenues would be reliant on the ability to bring increased manufacturing capacity during the last six months.

Despite the delays, seniority at Tissue Regenix claimed that there was still strong demand and does not expect long term issues past the time period specified.

Executive Chairman John Samuel said “We have strong global demand for our products, which allowed us to deliver continued revenue growth, demonstrated by DermaPure, which increased sales by 33% in the first half. We remain focused on short and medium term initiatives to increase capacity and alleviate supply constraints.”

Due to these manufacturing capability issues, shares in Tissue Regenix have fallen across Thursday trading. They currently value at 2.78p after experiencing a decline of 13.13%. 17/11/2019 14:40BST.

On a positive, Tissue Regenix announced receipt of a $300,000 grant to begin building a new 21,000 square foot facility in San Antonio, Texas.

The funds allocated would help upgrade utilities and infrastructure at the site, whilst technical staff needed to operate a second shift.

Even with the limitations, TRX have said that they plan to release additional products towards the end of 2019, giving shareholders optimism to hold onto shares.

Additionally, the company added that it was working with outsourcers to increase the yield of DermaPure, its soft tissue repair product. Firms have been flexible in Pharmaceuticals and health, seen with to Ra Pharmaceuticals Inc (NASDAQ: RARX), Yourgene Health PLC (LON: YGEN), Salarius Pharmaceuticals Inc (NASDAQ: SLRX).

The falls in the share price might only be short term, as TRX look to release more products and work to increase manufacturing then investors can take positives from the slower revenues in the third quarter.